In the sixth episode, season two of BoJack Horseman, autoerotic asphyxiation and celebrity deaths are recurrent discussions. In the episode, "Clyde Bruckmans Final Repose" of the TV series The X-Files, a psychic implies that special agent Fox Mulder will die by autoerotic asphyxiation. See also
Cerebral hypoxia
Choke hold
Choking game
Facesitting
Hypoxia
Self-bondage
Sexual fetishism

References
Further reading
Robert R. Hazelwood, Park Elliot Dietz, Ann Wolbert Burgess: Autoerotic Fatalities. Lexington, Mass. : LexingtonBooks, 1983. Sergey Sheleg, Edwin Ehrlich: Autoerotic Asphyxiation: Forensic, Medical, and Social Aspects, Wheatmark (15 August 2006), trade paperback, 208 pages ISBN 1587366045 ISBN 978-1587366048
John Money, Gordon Wainwright and David Hingsburger: The Breathless Orgasm: A Lovemap Biography of Asphyxiophilia. Buffalo, New York: Prometheus Books, 1991. External links

Well Hung: Death By Orgasm
Turvey B. "An Objective Overview of Autoerotic Fatalities"
The Medical Realities of Breath Control Play By Jay Wiseman
Is there a safe way to perform autoerotic asphyxiation? - Slate Magazine i
The results of a clinical trial examining the efficacy, tolerability and safety of adjunctive pimavanserin to risperidone and haloperidol were published in November 2012, and the results showed that pimavanserin potentiated the antipsychotic effects of subtherapeutic doses of risperidone and improved the tolerability of haloperidol treatment by reducing the incidence of extrapyramidal symptoms.The drug met expectations for a Phase III clinical trial for the treatment of Parkinsons disease psychosis, and has completed Phase II trials for adjunctive treatment of schizophrenia alongside an antipsychotic medication.On September 2, 2014, the United States Food and Drug Administration granted Breakthrough Therapy status to Acadias New Drug Application for pimavanserin. FDA Approval
On April 29, 2016 Nuplazid (pimavanserin) was approved by the FDA for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The non-binding advisory panel recommendation of 12-to-2 in support of approval that preceded the FDA approval action noted that the drug met an important need, despite its only providing modest benefits and posing serious safety issues.On June 29, 2018 the FDA approved new dosages of pimavanserin to treat hallucinations and delusions associated with Parkinson’s disease psychosis. A 34 mg capsule and 10 mg tablet formulation were approved. Previously, patients were required to take two 17 mg tablets to achieve the recommenced 34 mg dose per day. The 10 mg dose is indicated for patients also taking CYP3A4 inhibitors (eg. ketoconazole). HARMONY-Trial
In a phase 3, double-blind, randomized, placebo-controlled trial (ClinicalTrials.gov number NTC03325556) pimavanserin was applicated in patients with dementia-related psychosis.